Targeting important unmet medical needs

Corporate Presentation

September 2021

Forward-Looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' (formerly Auris Medical) strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2020, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

2

Altamira

Therapeutics

at a Glance

Legacy programs provide potential opportunity to unlock value for investors in the medium-term via spinoff/divestiture

Respiratory - Altamira Medica:

  • Bentrio™allergens(AM-301) for protection against airborne viruses and Neurotology - Auris Medical:
  • AM-125for treating acute vertigo
  • Sonsuvi ® (AM-211) for treating acute inner ear hearing loss
  • Keyzilen® (AM-101) for treating acute inner ear tinnitus

Transformative acquisition and merger in Summer 2021

  • Acquired Trasir Therapeutics (WU spinoff) and subsequently merged into Auris Medical

Repositioning around RNA therapeutics

  • Trasir a pioneer in extrahepatic oligonucleotide delivery
  • > 15 years of NIH funded research
  • Versatile peptide-based OligoPhoreTM / SemaPhoreTM platform

Initiated preclinical development of first RNA pipeline program off OligoPhore™ platform

  • AM-401for treatment of mutant KRAS-driven cancer

3

Altamira Group

Medical devices

Therapeutics for

RNA therapeutics for

for protection against

inner ear disorders

extrahepatic targets

airborne allergens

and viruses

4

Leadership Team

Thomas Meyer | PhD

Samuel Wickline | MD

Elmar Schärli | CPA

CEO and Chairman

Chief Scientific Officer

Chief Financial Officer

Founder Auris Medical

Prof. of Cardiovascular Sciences,

~30 years private and

14 years with Disetronic Group

Molecular Physiology and Pharmacology,

public company

incl. CEO and BoD member

Medical Engineering at USF

finance and accounting

>20% sales CAGR

Former Prof. of Medicine, Physics,

experience in biotech

$3 bn market cap

Biomedical Engineering, Cell Biology

and medtech

and Physiology at Wash U

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Disclaimer

Altamira Therapeutics Ltd. published this content on 16 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2021 15:41:09 UTC.